Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation
Allogeneic hematopoietic cell transplantation (alloHCT) has been established as a standard of care for patients with different disorders of the hematopoietic system. In many indications, the transfer of healthy donor cells represents the only chance for cure and improves survival chances significantly. Acute graft-versus-host-disease (aGVHD) is the main cause of morbidity and nonrelapse mortality (NRM) following alloHCT [1]. Early diagnosis of aGVHD is the main challenge during follow-up after alloHCT. (Source: Experimental Hematology)
Source: Experimental Hematology - January 13, 2022 Category: Hematology Authors: Abed A. Sarraf, Johannes Schetelig, Henning Baldauf, Friedrich St ölzel, Jan Moritz Middeke, Katja Sockel, Raphael Teipel, Stefan Brückner, Marco Berning, Sebastian Zeissig, Jana Babatz, Gustavo B. Baretton, Jochen Hampe, Martin Bornhäuser, Daniela Aus Tags: Article Source Type: research
Macroscopic, Histologic and Clinical Assessment of Acute GVHD of the Upper Gastrointestinal Tract within 6 Weeks after Allogeneic Hematopoietic Cell Transplantation
Allogeneic hematopoietic cell transplantation (alloHCT) has been established as a standard of care for patients suffering from different disorders of the hematopoietic system. In many indications, the transfer of healthy donor cells represents the only chance for cure and improves survival chances significantly. Acute graft-versus-host-disease (aGVHD) is the main cause of morbidity and non-relapse mortality (NRM) following alloHCT(1). Early diagnosis of aGVHD is the main challenge during follow-up after alloHCT. (Source: Experimental Hematology)
Source: Experimental Hematology - January 13, 2022 Category: Hematology Authors: Abed A. Sarraf, Johannes Schetelig, Henning Baldauf, Friedrich St ölzel, Jan Moritz Middeke, Katja Sockel, Raphael Teipel, Stefan Brückner, Marco Berning, Sebastian Zeissig, Jana Babatz, Gustavo B. Baretton, Jochen Hampe, Martin Bornhäuser, Daniela Aus Source Type: research
Megakaryocyte –stromal cell interactions: Effect on megakaryocyte proliferation, proplatelet production, and survival
Bone marrow stromal cells provide a proper environment for the development of hematologic lineages. The incorporation of different stromal cells into in vitro culture systems would be an attractive model to study megakaryopoiesis and thrombopoiesis. Our objective was to evaluate the participation of different types of stromal cells in in vitro megakaryopoiesis, thrombopoiesis, and megakaryocyte (MK) survival. CD34-positive progenitors from umbilical cord blood were differentiated into MK precursors and the n cocultured with umbilical vein endothelial cells (HUVECs), bone marrow mesenchymal stem cells (MSCs), skin fibrobl...
Source: Experimental Hematology - January 12, 2022 Category: Hematology Authors: Nora P. Goette, Francisco R. Borzone, Ailen D. Discianni Lupi, Norma A. Chasseing, Mar ía F. Rubio, Mónica A. Costas, Paula G. Heller, Rosana F. Marta, Paola R. Lev Tags: Regular Submission Source Type: research
Megakaryocyte-stromal cell interactions: effect on megakaryocyte proliferation, proplatelet production, and survival
The bone marrow (BM) microenvironment is composed of different stromal cell types, extracellular matrix components and soluble/humoral factors, which provide physical support and modulate survival, proliferation and maturation of hematopoietic stem and committed cells, including megakaryocytes (MKs) (1). Megakaryopoiesis is closely regulated by both, transcription factors and signals derived from the interaction of hematopoietic stem cells with BM environmental cells (2, 3). Despite numerous advances in recent years regarding the mechanisms involved in megakaryopoiesis and thrombopoiesis, there are still a number of unansw...
Source: Experimental Hematology - January 12, 2022 Category: Hematology Authors: Nora P. Goette, Francisco R. Borzone, Ailen D. Discianni Lupi, Norma A. Chasseing, Mar ía F. Rubio, Mónica A. Costas, Paula G. Heller, Rosana F. Marta, Paola R. Lev Tags: Article Source Type: research
C/EBP β sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module
The MYB gene was initially discovered as the cellular progenitor of the retrovirally-transduced oncogene v-myb of avian leukemia virus (AMV), an agent that causes myeloid leukemia in chickens. Subsequent work showed that MYB encodes a transcription factor (MYB) that is highly expressed in hematopoietic progenitor cells and supports their proliferation and differentiation (for review see [1]). MYB binds to a short consensus nucleotide motif via an N-terminal DNA-binding domain and stimulates the transcription of its target genes by a transactivation domain located in the center of the protein (Fig. (Source: Experimental Hematology)
Source: Experimental Hematology - January 12, 2022 Category: Hematology Authors: Karl-Heinz Klempnauer Tags: Perspective Source Type: research
Greetings from your Editorial Team
This year it seems particularly relevant to celebrate and give thanks to all who have helped the world begin to emerge from a very trying period. Within the community served and managed by Experimental Hematology, we also have good reasons to anticipate a bright future. This is due to the unprecedented rigor and speed of action of our associate editors, editorial board, and our scientific editor, plus increasingly helpful input from our Elsevier support staff, the staff of ISEH, and our energetic Publications Committee. (Source: Experimental Hematology)
Source: Experimental Hematology - December 29, 2021 Category: Hematology Authors: Connie Eaves Tags: Editorial Source Type: research
Cover 2: Editorial Board
(Source: Experimental Hematology)
Source: Experimental Hematology - December 29, 2021 Category: Hematology Source Type: research
Hematopoietic stem cell gene editing and expansion: state-of-the-art technologies and recent applications
Hematopoietic stem cells (HSCs) are a rare bone marrow (BM) population of cells that are multipotent and able to self-renew, and can therefore stably reconstitute the entire hematopoietic system following transplantation [1, 2]. This concept forms the basis for HSC transplantation (HSCT) therapies. These currently involve ablating a patient's dysfunctional hematopoietic system by radiation/chemotherapy and subsequent transplantation of healthy donor HSCs to reform a functional hematopoietic system within the patient. (Source: Experimental Hematology)
Source: Experimental Hematology - December 29, 2021 Category: Hematology Authors: Myriam L.R. Haltalli, Adam C. Wilkinson, Alejo Rodriguez-Fraticelli, Matthew Porteus Source Type: research
EVI1 protein interaction dynamics: targetable for therapeutic intervention?
High expression of the transcriptional regulator EVI1 encoded at the MECOM locus at 3q26 is one of the most aggressive oncogenic drivers in acute myeloid leukaemia (AML) and carries a very poor prognosis. How EVI1 confers leukaemic transformation and chemotherapy resistance in AML is subject to important ongoing clinical and experimental studies. Recent discoveries have revealed critical details about genetic mechanisms of the activation of EVI1 overexpression and downstream events of aberrantly high EVI1 expression. (Source: Experimental Hematology)
Source: Experimental Hematology - December 23, 2021 Category: Hematology Authors: Roberto Paredes, Nora Doleschall, Kathleen Connors, Bethany Geary, Stefan Meyer Tags: Perspective Rev 1 Source Type: research
Humanized three-dimensional scaffold xenotransplantation models for myelodysplastic syndromes
Myelodysplastic syndromes (MDS) constitute a heterogeneous group of malignant hematopoietic stem cell disorders that predominantly affect older individuals, with an incidence of approximately 5 –13 per 100,000 persons/year [1–5]. Clinically, the disease is characterized by ineffective production of mature blood cells and an increased risk of progression to acute myeloid leukemia. The molecular pathogenesis is heterogeneous and frequently consists of the acquisition of multiple molecula r lesions in hematopoietic stem cells such as cytogenetic aberrations and recurrent mutations in genes of essential pathways, including...
Source: Experimental Hematology - December 21, 2021 Category: Hematology Authors: Eva Altrock, Carla Sens-Albert, Johann-Christoph Jann, Johanna Flach, Vladimir Riabov, Nanni Schmitt, Qingyu Xu, Arwin Mehralivand, Anna Hecht, Laurenz Steiner, Alexander Streuer, Verena Nowak, Julia Obl änder, Nadine Weimer, Iris Palme, Ahmed Jawhar, Cl Tags: Regular Submission Source Type: research
Humanized 3D scaffold xenotransplantation models for Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell (HSC) disorders that predominantly affect older individuals with an incidence of approximately 5-13 per 100,000 persons/year 1 –5. Clinically, the disease is characterized by ineffective production of mature blood cells and an increased risk of progression to acute myeloid leukemia (AML). The molecular pathogenesis is heterogeneous and frequently consists of the acquisition of multiple molecular lesions in hematopoietic s tem cells HSC such as cytogenetic aberrations and recurrent mutations in genes of essential pathways, inclu...
Source: Experimental Hematology - December 21, 2021 Category: Hematology Authors: Eva Altrock, Carla Sens-Albert, Johann-Christoph Jann, Johanna Flach, Vladimir Riabov, Nanni Schmitt, Qingyu Xu, Arwin Mehralivand, Anna Hecht, Laurenz Steiner, Alexander Streuer, Verena Nowak, Julia Obl änder, Nadine Weimer, Iris Palme, Ahmed Jawhar, Cl Source Type: research
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in Non-Hodgkin lymphoma patients within six months after treatment
The novel Coronavirus Covid-19 has afflicted millions of people worldwide. Several vaccines have been developed to contain the pandemic. The BNT162b2 vaccine tested in 43,548 participants, showed a 95% protection against Covid-19 [1]. Comparable results were achieved in a phase III trial testing the mRNA-1273 [2]. Based on these results, BNT162b2 and mRNA 1273 received global approval and individuals are being vaccinated worldwide. (Source: Experimental Hematology)
Source: Experimental Hematology - December 21, 2021 Category: Hematology Authors: Ariella Tvito, Aaron Ronson, Renan Ghosheh, Mira Kharit, Jakob Ashkenazi, Sophie Magen, Ellen Broide, Emmanuel Benayoun, Jacob M Rowe, Yishai Ofran, Chezi Ganzel Tags: Brief communication Source Type: research
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasm
The JAK2 V617F mutation is a somatic mutation found in most patients with myeloproliferative neoplasms (MPNs) [1]. The mutation causes constitutive JAK –STAT pathway activation in hematopoietic stem and progenitor cells (HSPCs), leading to overproduction of red blood cells, platelets, and white blood cells and/or bone marrow fibrosis. Previous work characterizing JAK2-mutant mouse models [2,3] and MPN patient samples [4] has revealed that JAK2 V6 17F increases the fitness of hematopoietic stem cells (HSCs) and promotes megakaryocyte–erythroid differentiation. (Source: Experimental Hematology)
Source: Experimental Hematology - December 15, 2021 Category: Hematology Authors: Debra Van Egeren, Baransel Kamaz, Shichen Liu, Maximilian Nguyen, Christopher R. Reilly, Maria Kalyva, Daniel J. DeAngelo, Ilene Galinsky, Martha Wadleigh, Eric S. Winer, Marlise R. Luskin, Richard M. Stone, Jacqueline S. Garcia, Gabriela S. Hobbs, Franzi Tags: Brief Communication Source Type: research
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in myeloproliferative neoplasm patients
The JAK2-V617F mutation is a somatic mutation found in the majority of patients with myeloproliferative neoplasms (MPNs)1. The mutation causes constitutive JAK-STAT pathway activation in hematopoietic stem and progenitor cells (HSPCs), leading to overproduction of red blood cells, platelets, white blood cells, and/or bone marrow fibrosis. Previous work characterizing JAK2-mutant mouse models2,3 and MPN patient samples4 have shown that JAK2-V617F increases the fitness of hematopoietic stem cells (HSCs) and promotes megakaryocyte-erythroid differentiation. (Source: Experimental Hematology)
Source: Experimental Hematology - December 15, 2021 Category: Hematology Authors: Debra Van Egeren, Baransel Kamaz, Shichen Liu, Maximilian Nguyen, Christopher R. Reilly, Maria Kalyva, Daniel J. DeAngelo, Ilene Galinsky, Martha Wadleigh, Eric S. Winer, Marlise R. Luskin, Richard M. Stone, Jacqueline S. Garcia, Gabriela S. Hobbs, Franzi Tags: Brief Communication Source Type: research
CD99 in Malignant Hematopoiesis
CD99 was first discovered in 1979 as human thymus-leukemia antigen.1 CD99 is a highly O-glycosylated transmembrane protein encoded by the CD99 or previously known as MIC2 gene.2 CD99 is located in the pseudoautosomal region (PAR) of the Y (Yp11-Ypter) and X (Xp22.33-Xpter) chromosomes in humans.3,4 The CD99 gene encodes two distinct proteins: a wild-type full-length CD99 long isoform (CD99 L) with 185 amino acids (molecular weight of 32 kDa) and a truncated short isoform (CD99 S) with 161 amino acids as consequence of alternative splicing (28 kDa). (Source: Experimental Hematology)
Source: Experimental Hematology - December 13, 2021 Category: Hematology Authors: Atham Ali, Pooja Vaikari, Houda Alachkar Source Type: research
